Koers Santhera Pharmaceuticals Holding AG Xetra
Aandelen
S3F
CH0027148649
Farmaceutische producten
Omzet 2024 * | 51,09 mln. 56,96 mln. 52,75 mln. | Omzet 2025 * | 60 mln. 66,89 mln. 61,94 mln. | Marktkapitalisatie | 88,46 mln. 98,63 mln. 91,33 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -35 mln. -39,02 mln. -36,13 mln. | Nettowinst (verlies) 2025 * | -10 mln. -11,15 mln. -10,32 mln. | EV/omzet 2024 * | 1,73 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,47 x |
K/w-verhouding 2024 * |
-3,42
x | K/w-verhouding 2025 * |
-12,8
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 65,98% |
Recentste transcriptie over Santhera Pharmaceuticals Holding AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Dario Eklund
CEO | Chief Executive Officer | 56 | 01-12-19 |
Thomas Meier
FOU | Founder | 62 | 07-09-04 |
Andrew Smith
DFI | Director of Finance/CFO | 61 | 01-04-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Meier
FOU | Founder | 62 | 07-09-04 |
Director/Board Member | 56 | 04-04-17 | |
Otto Schwarz
BRD | Director/Board Member | 68 | 27-06-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,88% | 80,5 mld. | |
+14,11% | 9,15 mld. | |
-14,14% | 4,9 mld. | |
+43,39% | 4,49 mld. | |
+18,90% | 4,44 mld. | |
+7,93% | 2,19 mld. | |
-28,40% | 2,13 mld. | |
+15,93% | 2,1 mld. | |
-43,17% | 1,78 mld. |